Trade Alert: Big News In Biotech

The FDA just removed a regulatory roadblock from one of our Multbaggers names.

Here’s What Changed

One of the names we’re trading today is uniQure (QURE 0.00%↑), a current Multibaggers list stock.

For newer readers, the Multibaggers list is a curated set of X accounts run by analysts and traders with documented histories of identifying stocks that have gone on to deliver 100%+ gains. It’s not about volume or noise—it’s about signal.

Earlier this year, QURE exploded higher after announcing what appeared to be the first truly effective treatment for Huntington’s Disease. The move was so dramatic that even Martin Shkreli publicly suggested the stock could ultimately go 5× or even 10× from there, given the size of the unmet need and the implied value of a working therapy.

Then came the rug pull.

In November, the FDA rejected a key component of uniQure’s regulatory strategy—specifically its use of external control data—sending the stock into a tailspin and forcing the market to reprice in the risk of a long, expensive new trial. The thesis didn’t just wobble; it collapsed.

That changed yesterday.

The FDA released new guidance that explicitly removes the very barrier that crushed QURE last month. In plain English: the agency just reopened a regulatory pathway the market had assumed was closed. That doesn’t guarantee approval—but it dramatically alters the risk/reward calculus, especially after the stock has already been repriced for failure.

We’re taking advantage of that shift using a structure designed to keep the upside open while tightly defining the downside.

---

A Picks-and-Shovels Angle

We’re also opening a bullish trade in another Multibaggers list name that acts as a picks-and-shovels play on this theme.

This company doesn’t develop drugs itself. Instead, it provides specialized neurosurgical technology used to deliver advanced therapies directly into the brain—exactly the kind of infrastructure required for treatments like QURE’s.

When optimism around Huntington’s disease surged earlier this year, this stock surged with it. When the FDA pulled the rug, it was dragged down as well—despite no deterioration in its core technology or long-term role in the ecosystem.

If the regulatory outlook has truly shifted, this is the kind of second-order beneficiary that can move sharply once sentiment turns.

---

Two Top Names Trades

In addition to those two Multibaggers ideas, we’re also opening two new trades in names drawn directly from Portfolio Armor’s Top Ten list, which ranks securities by its estimate of their potential returns over the next six months.

Historically, Portfolio Armor Top Names have delivered strong forward returns versus the broader market, which you can track transparently here:
https://portfolioarmor.com/performance-top-names

All four trades share the same philosophy:

• defined downside,

• open-ended upside, and

• pre-wired exits, so we don’t have to babysit them.

Full details below.

Today’s First Top Names Trade

(Semiconductors / AI Infrastructure)